MET and MST1R as prognostic factors for classical Hodgkin's lymphoma
MET and MST1R as prognostic factors for classical Hodgkin's lymphoma
复制标题
DOI：
10.1038/modpathol.2013.64
复制
发表时间：
2013-09-01
期刊：
影响因子：
7.5
通讯作者：
Huh, Jooryung
中科院分区：
文献类型：
--
作者：
Koh, Young Wha;Park, Chansik;Huh, Jooryung
MST1R(RON)和MET是受体酪氨酸激酶基因家族成员，它们在细胞表面形成非共价复合体，是肿瘤进展的关键步骤。最近的一项研究表明，MET在霍奇金/里德-斯特恩伯格(HRS)细胞中的表达在经典型霍奇金淋巴瘤(CHL)中具有预后作用。本研究的目的是检测MET和MST1R在CHL中的表达对预后的意义。应用免疫组织化学和mRNA原位杂交技术检测100例CHL患者(中位年龄：32岁)MET和MST1R对预后的影响。中位随访时间为95个月(四分位数范围：42-126个月)。MET或MST1R蛋白的表达分别与MET或MST1R的高表达有关。38例患者(38%)HRS细胞表达MET蛋白，与总生存率相关(P=0.004)。26例患者(26%)表达MST1R蛋白，与总生存期(P=0.022)和无事件生存期(P=0.021)有关。多变量分析表明MET蛋白是影响总生存率的独立预后因素，MST1R蛋白是影响无事件生存率的独立预后因素。根据Ann Arbor分期进行亚组分析，MET和MST1R蛋白表达仅在晚期对预后有影响。特别是，MST1R和MET蛋白的共同表达与MET或MST1R单独表达或不表达相比，具有更好的生存结局。这项研究表明MET和MST1R是经典慢性淋巴细胞白血病的独立预后因素，可以识别需要更强化治疗的慢性淋巴细胞白血病患者的亚群。
MST1R (RON) and MET are receptor tyrosine kinase gene family members that form a noncovalent complex on the cell surface, a critical step in tumor progression. A recent study suggested a prognostic role of MET expression in Hodgkin/Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL). The purpose of this study was to examine the prognostic significance of MET and MST1R expression in cHL. The prognostic impact of MET and MST1R was examined in 100 patients with cHL (median age: 32 years) by immunohistochemistry and mRNA in situ hybridization. The median follow-up time was 95 months (interquartile range: 42-126 months). MET or MST1R protein expression was associated with high MET or MST1R mRNA expression, respectively. Thirty-eight patients (38%) expressed MET protein in HRS cell, which was associated with better overall survival (P=0.004). Twenty-six patients (26%) expressed MST1R protein, which was associated with better overall survival (P=0.022) and event-free survival (P=0.021). Multivariate analysis identified MET protein as an independent prognostic factor for overall survival and MST1R protein as an independent prognostic factor for event-free survival. Subgroup analysis according to Ann Arbor stage showed that expressions of MET and MST1R protein have prognostic impact in the advanced stage only. In particular, coexpression of MST1R and MET protein was associated with a better survival outcome than MET or MST1R expression alone or no expression. This study suggests that MET and MST1R are independent prognostic factors in classical cHL, and may allow the identification of a subgroup of cHL patients who require more intensive therapy.